Immunoglobulin E specific for Dermatophagoides pteronyssinus allergens (sIgE-HDM)

Immunoglobulin E (IgE) specific for Dermatophagoides pteronyssinus allergens is a specialized antibody that plays a central role in the pathogenesis of house dust mite (HDM) allergies. In sensitized individuals, these IgE molecules are produced by B cells and bind to high-affinity FcεRI receptors on the surface of mast cells and basophils (Source: PubMed, PMID: 29351914). When the individual is exposed to D. pteronyssinus allergens, such as Der p 1 or Der p 2, the allergens cross-link the surface-bound IgE, triggering the immediate release of inflammatory mediators like histamine and leukotrienes (Source: World Allergy Organization). This process leads to the clinical manifestations of allergic rhinitis, perennial asthma, and atopic dermatitis. Therapeutic strategies include the use of omalizumab, a monoclonal antibody that binds to the Fc region of circulating IgE to prevent its attachment to effector cells (Source: FDA). Furthermore, allergen immunotherapy (AIT) utilizes HDM extracts to desensitize the immune system, shifting the balance from an IgE-mediated response to a protective IgG4-mediated response (Source: NIH). Measurement of these specific IgE levels is a standard diagnostic tool for identifying HDM sensitivity and monitoring the efficacy of desensitization treatments (Source: Mayo Clinic).

Other names

House dust mite-specific IgEAnti-Dermatophagoides pteronyssinus IgED. pteronyssinus-specific IgEHDM-specific IgESpecific IgE to D. pteronyssinus

Omalizumab binds to the Cε3 domain of circulating IgE, preventing its interaction with high-affinity IgE receptors (FcεRI) on mast cells and basophils, thereby inhibiting the allergic cascade (Source: PubMed, PMID: 25151858). Allergen immunotherapy (AIT) induces immune tolerance by promoting the production of allergen-specific IgG4 'blocking' antibodies that compete with IgE for allergen binding (Source: NIH).